SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
5 Unspoken Rules You Need to Know When Starting a Media Agency
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
5 Unspoken Rules You Need to Know When Starting a Media Agency
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
5 Unspoken Rules You Need to Know When Starting a Media Agency
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
S&P 500   3,744.52
DOW   29,926.94
QQQ   279.76
5 Unspoken Rules You Need to Know When Starting a Media Agency
Live Updates: Russia-Ukraine War
Box Inc. Stock on Track to Become a Q4 Winner
3 Stocks With Market-Beating Price Performance
Don’t Chase American Virtual Cloud Technologies Higher
Is Ford's Revenue Enough to Juice its Stock Price?
Will WWE Shares Wrestle Their Way Higher or Will They Tap Out?
NASDAQ:LOGC

LogicBio Therapeutics - LOGC Stock Forecast, Price & News

$2.03
0.00 (0.00%)
(As of 10/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.02
$2.03
50-Day Range
$0.27
$2.03
52-Week Range
$0.26
$4.53
Volume
667,478 shs
Average Volume
1.06 million shs
Market Capitalization
$66.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.83

LogicBio Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
335.1% Upside
$8.83 Price Target
Short Interest
Healthy
0.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.49
Upright™ Environmental Score
News Sentiment
0.17mentions of LogicBio Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.72) to ($0.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

348th out of 1,075 stocks

Biological Products, Except Diagnostic Industry

55th out of 170 stocks

LOGC stock logo

About LogicBio Therapeutics (NASDAQ:LOGC) Stock

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Receive LOGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LOGC Stock News Headlines

AstraZeneca acquires local startup at 660% premium
LogicBio Therapeutics Inc
Recap: LogicBio Therapeutics Q2 Earnings
LogicBio Therapeutics Inc - Stock Quote LOGC
LogicBio Says FDA Lifts Clinical Hold On LB-001 IND
Clinical Development Update from Portfolio Company LogicBio
See More Headlines
Receive LOGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LOGC Company Calendar

Last Earnings
11/15/2021
Today
10/07/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LOGC
Fax
N/A
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.83
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+335.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-40,030,000.00
Net Margins
-304.61%
Pretax Margin
-304.88%

Debt

Sales & Book Value

Annual Sales
$5.41 million
Book Value
$0.93 per share

Miscellaneous

Free Float
30,293,000
Market Cap
$66.91 million
Optionable
Not Optionable
Beta
1.61

Key Executives

  • Mr. Frederic Chereau M.B.A.Mr. Frederic Chereau M.B.A. (Age 55)
    Pres, CEO & Director
    Comp: $793.2k
  • Dr. Mark A. Kay M.D. (Age 64)
    Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director
    Comp: $107.5k
  • Dr. Daniel J. Gruskin M.D. (Age 50)
    Chief Medical Officer
    Comp: $577.48k
  • Dr. Leszek Lisowski M.B.A.
    Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. Adi Barzel Ph.D.
    Co-Founder
  • Mr. Joshua Blacher (Age 49)
    Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Matthias Hebben Ph.D.
    Global VP & Head of Technology Devel.
  • Dr. Mariana Nacht Ph.D. (Age 58)
    Chief Scientific Officer
  • Ms. Andrea Paul J.D. (Age 41)
    Gen. Counsel & Corp. Sec.
  • Ms. Grace Lochhead
    VP & Head of HR













LOGC Stock - Frequently Asked Questions

Should I buy or sell LogicBio Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LOGC shares.
View LOGC analyst ratings
or view top-rated stocks.

What is LogicBio Therapeutics' stock price forecast for 2022?

4 equities research analysts have issued 1 year price objectives for LogicBio Therapeutics' shares. Their LOGC share price forecasts range from $2.50 to $16.00. On average, they expect the company's stock price to reach $8.83 in the next year. This suggests a possible upside of 335.1% from the stock's current price.
View analysts price targets for LOGC
or view top-rated stocks among Wall Street analysts.

How have LOGC shares performed in 2022?

LogicBio Therapeutics' stock was trading at $2.31 at the start of the year. Since then, LOGC shares have decreased by 12.1% and is now trading at $2.03.
View the best growth stocks for 2022 here
.

When is LogicBio Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our LOGC earnings forecast
.

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.01. The company earned $2.12 million during the quarter, compared to analyst estimates of $5.02 million. LogicBio Therapeutics had a negative net margin of 304.61% and a negative trailing twelve-month return on equity of 107.56%.

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an IPO on Friday, October 19th 2018. The company issued 5,800,000 shares at a price of $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $2.03.

How much money does LogicBio Therapeutics make?

LogicBio Therapeutics (NASDAQ:LOGC) has a market capitalization of $66.91 million and generates $5.41 million in revenue each year. The company earns $-40,030,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The official website for the company is www.logicbio.com. The company can be reached via phone at (617) 245-0399 or via email at michael@sternir.com.

This page (NASDAQ:LOGC) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.